GDF-15

GDF-15 Molekülinformation

Englischer Name	Growth/differentiation factor 15	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	10	Target-Alias	Placental TGF-beta，GDF-15，MIC1，PTGFB，MIC-1，PLAB，NSAID-activated gene 1 protein，Growth Differentiation Factor 15，Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1，Placental Bone Morphogenetic Protein，NRG-1，PDF，Growth/Differentiation Factor 15，Macrophage Inhibitory Cytokine-1，PTGF-Beta，NSAID-regulated gene 1 protein，GDF15，Prostate Differentiation Factor，Macrophage Inhibitory Cytokine 1，NAG-1，NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Growth/differentiation factor 15
Target-Alias	Placental TGF-beta，GDF-15，MIC1，PTGFB，MIC-1，PLAB，NSAID-activated gene 1 protein，Growth Differentiation Factor 15，Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1，Placental Bone Morphogenetic Protein，NRG-1，PDF，Growth/Differentiation Factor 15，Macrophage Inhibitory Cytokine-1，PTGF-Beta，NSAID-regulated gene 1 protein，GDF15，Prostate Differentiation Factor，Macrophage Inhibitory Cytokine 1，NAG-1，NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	10
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

GDF-15 Produktliste

Attribut
Protein (6)Kits (1)
Produktbibliothek
Online (7)
Spezies
Human (5)Cynomolgus (1)Mouse (1)
Etikett
His Tag (3)Fc Tag (1)Avi Tag & Fc Tag (1)His Tag & Avi Tag (1)- (1)
Marker
Unconjugated (4)Biotin-labeled (2)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT GD5-H5149	Human	E. coli	Human GDF-15 / MIC-1 Protein, His Tag, low Endotoxin	In den Warenkorb legen
HOT GD5-H5269	Human	HEK293	Human GDF-15 / MIC-1 Protein, Fc Tag (MALS verified)	In den Warenkorb legen
HOT GD5-H81Q3	Human	E. coli	Biotinylated Human GDF-15 / MIC-1 Protein, His,Avitag™	In den Warenkorb legen
HOT GD5-C5148	Cynomolgus	E. coli	Cynomolgus GDF-15 / MIC-1 Protein, His Tag, low endotoxin	In den Warenkorb legen
CEA-C077	Human	-	Human GDF-15 ELISA Kit	In den Warenkorb legen
GD5-H82F9	Human	HEK293	Biotinylated Human GDF-15 / MIC-1 Protein, Avitag™, Fc Tag (MALS verified)	In den Warenkorb legen
GD5-M5149	Mouse	E. coli	Mouse GDF-15 / MIC-1 Protein, His Tag	In den Warenkorb legen

Gesamtmenge7

GDF-15 Molekülhintergrund

Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.

GDF-15 Molekülalias

GDF15,GDF-15,MIC-1,MIC1,NAG-1,PDF,PLAB,PTGFB,NRG-1

Antikörperprojekt-Handelsplattform

Projektname	Projektphase	Molekültyp	Molekülquelle	Krankheitsgebiet	Indikationen
GDF15 mAb - 01	PCC	Monoclonal	Humanized Mouse	Metabolism	Solid tumor,Cancer cachexia

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Visugromab	CTL-002	Phase 3 Clinical	CatalYm GmbH	Cachexia; Carcinoma, Non-Small-Cell Lung; Solid tumours; Urinary Bladder Neoplasms	Details
Ponsegromab	PF-06946860	Phase 3 Clinical	Pfizer Inc	Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Fatigue; Feeding and Eating Disorders; Heart Failure; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms	Details
NGM-120	NGM-120	Phase 2 Clinical	NGM Biopharmaceuticals Inc	Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Hyperemesis Gravidarum; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms	Details
GDF15 agonist (Lilly)		Phase 1 Clinical	Eli Lilly And Company	Diabetes Mellitus	Details
NN-9215	Human-GDF15; MIC-1; NN-9215; LA-GDF15	Phase 1 Clinical	Novo Nordisk A/S	Obesity	Details
GFS-202-A	GFS-202-A; GFS202A	Phase 1 Clinical	Genfleet Therapeutics (Shanghai) Co Ltd	Cachexia	Details
GB-18	GB-18; GB18	Phase 1 Clinical	Shandong Kexing Bio-Products Co Ltd	Cachexia	Details
CIN-109	CIN-109; JNJ-9090	Phase 1 Clinical	Janssen Sciences Ireland Unlimited Company	Obesity	Details
MBL-949	MBL-949	Phase 1 Clinical	Novartis Pharma Ag	Diabetes Mellitus; Obesity	Details
AV-380	AV-380	Phase 1 Clinical	Aveo Pharmaceuticals Inc	Cachexia	Details